BLCO - Bausch + Lomb Corporation

...

Available for logged in users only.

The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.

• Bausch + Lomb Non-GAAP EPS of $0.24 beats by $0.07, revenue of $1.17B beats by $70M
• Bausch + Lomb Q4 2023 Earnings Preview
• Eminence Capital adds Sea, AMD stakes; exits Peloton, Bausch + Lomb in Q4
• Bausch + Lomb draws double downgrade at J.P. Morgan on spinoff concerns
• Bausch + Lomb drops amid comments at JPMorgan Healthcare Conference
• Bausch Health gains after an appeals hearing in Norwich case over generic Xifaxan
• Bausch + Lomb wins FDA nod for eye surgery product
• FDA’s new drug approvals for 2023 rise 51% from last year
• Bausch + Lomb Non-GAAP EPS of $0.22 beats by $0.03, revenue of $1B beats by $9.86M
• Bausch + Lomb prices $1.4B notes offering
• Bausch + Lomb to raise debt to finance Novartis deal
• Bausch + Lomb beats Q2 top line estimates, raises FY guidance
• Bausch + Lomb creates 2 new roles as part of changes to executive leadership team
• Bausch + Lomb buys Blink eye drops from Johnson & Johnson
• Bausch + Lomb to buy dry-eye therapy from Novartis for over $1B
• Bausch Health downgraded at Cowen as stock is fairly valued
• Morgan Stanley sees broader MedTech impact from weight loss drugs
• Bausch + Lomb and Novaliq win FDA nod for dry eye disease therapy
• Bausch Health rise continues; up another 9%
• Bausch Health soars amid skinny label court decision vs Norwich over Xifaxan drug (update)